Absolute
Revitalizing immuno-oncology’s promise with next-generation T cell engagers
Precision
We are dedicated to transforming the lives of patients everywhere by mastering the discovery, development and delivery of off-the-shelf precision immunotherapies
Immuno-oncology has produced tremendous results for some cancer patients – even cures. But it still has vast untapped potential to help those whose cancers do not respond to current treatments.
Clasp Therapeutics® is expanding the reach of immuno-oncology with precision T cell engagers (TCEs) that enable the immune system to identify and specifically destroy tumors harboring common driver mutations, regardless of tumor type. This approach enables a highly selective paradigm where every patient has the right biologic machinery to respond to treatment.
Using cancer-specific markers to precisely and selectively target tumor cells for destruction
Clasp targets mutated protein fragments, or peptides, that are displayed as complexes with Human Leukocyte Antigen (HLA) molecules on the surface of cancer cells. These mutant peptide-HLA complexes act as a molecular fingerprint unique to the tumor — a distinctive marker created by oncogenic mutations and presented through the cell’s natural antigen presentation machinery.
By leveraging this mechanism, Clasp can access the vast majority of cancer-driving proteins that exist only inside the cell and are invisible to traditional antibody-like drugs. And because these mutant peptide-HLA complexes are found only on cancer cells, Clasp’s TCEs are designed to attack with precision, sparing normal tissue and minimizing the risk of toxicity.
Oncogenic drivers enable exquisite tumor specificity
Achieving high-precision anti-tumor activity with antibody-like T cell engagers
We target these cancer-specific protein fragments with pHLAre™ molecules, Clasp's proprietary precision HLA redirecting engagers, which are designed to draw T cells into close contact with tumor cells. The resulting immune synapse mimics the natural HLA molecule-T cell receptor interface, triggering T cells to destroy tumor cells, while sparing non-malignant cells.
Modular patient- and tumor-specific TCEs
KRas: a high impact, durable target for precision TCEs
KRas mutations drive some of the hardest-to-treat cancers, including pancreatic, colorectal and lung tumors. While KRas small molecules have clear clinical activity, responses are typically short-lived and resistance inevitably emerges. Because KRas mutations arise early in tumorigenesis and remain conserved through metastasis and treatment resistance, they represent durable, high-impact targets for precision immunotherapy, even after progression on a KRas small molecule inhibitor.
Achieving precision by targeting cancer's drivers
Pipeline
"Aim to Cure" is our guiding principle. At Clasp we are committed to translating cutting-edge research into meaningful medicines for patients. We merge a deep understanding of cancer genetics with extensive experience growing successful clinical-stage immuno-oncology companies to develop meaningful innovations for people suffering from cancer. We foster an environment of passion, inclusion and true teamwork.
-
![]()
As Clasp’s first employee, it has been incredibly rewarding for me to see our science progress from in vitro assays to planning for clinical trials. I really believe in our scientific approach, and I can’t wait to see the difference that we can make.
Justina Caushi, PhD
Senior Scientist -
![]()
At Clasp, everyone is willing to jump in, to learn, to help and to work hard to further our goal of making good medicines that can be delivered to people in need.
Ron Copeland, PhD
Director, Analytical & Formulation Development -
![]()
Every person at Clasp has a voice, and I feel wholeheartedly welcomed to be myself while contributing scientific work that I can be proud of. This is one of the most rewarding environments I’ve ever worked in.
Brena Williams
Principal Scientist of Upstream Process Development -
![]()
Clasp’s patient focus inspires me in my work every day. I chose a career in clinical operations to help bring new therapies to patients in need, and I believe we can have a direct impact on improving patient lives.
Julia Shepherd
Senior Director, Clinical Operations
Investors
Our Core Values
At Clasp, our core values are foundational to everything we do. We believe that by staying true to these values, we can make a meaningful impact on our patients, our Claspians, and our community.
Join the Clasp Team
We are an ambitious team that is committed to innovating and expanding the clinical potential of the latest discoveries in oncology. Join us in our drive to advance new therapies.
If you see yourself as a part of our team, send your resume and cover letter to careers@clasptx.com.
Press Releases, Media & Presentations
Collaborate with Clasp
Clasp welcomes discussions with potential partners around developing TCEs that are highly tumor-specific. To explore collaboration opportunities, email partner@clasptx.com.
Learn more about GUARDIAN-101, our ongoing Phase 1 trial of CLSP-1025 by visiting our ClinicalTrials.gov listing NCT06778863.
EMAIL US DIRECTLY
PARTNER
partner@clasptx.com
MEDIA
media@clasptx.com
CAREERS
careers@clasptx.com
GENERAL INQUIRES
info@clasptx.com
OUR LOCATIONS
Corporate Headquarters:
Cambridge, MA
Alexandria Center at One Kendall Square Building 600/700, Suite 7-202
Rockville, MD
1450 Research Boulevard, Suite 120
